Buchumschlag

Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Benjamin J. Lee, Jenny Liu, Shawn P. Griffin, Jean Doh, Stefan O. Ciurea, Piyanuch Kongtim, Elizabeth A. Brem
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Cancer Medicine
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?
von: Santino Caserta, et al.
Veröffentlicht: (2025)

APE1 Attenuates ALK Tyrosine Kinase Inhibitors Sensitivity in NPM1‐ALK Positive Anaplastic Large Cell Lymphoma
von: Zheng Liu, et al.
Veröffentlicht: (2025)

Healthcare Resource Utilization and Costs in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Treated With Covalent Bruton's Tyrosine Kinase Inhibitors: Real‐World Impact of Cardiovascular Adverse Events
von: Mavis Obeng‐Kusi, et al.
Veröffentlicht: (2025)

Rapid HHV ‐6 Clearance Following Preemptive Short‐Course Foscarnet in Allogeneic Stem Cell Transplant Recipients
von: Piyatida Chumnumsiriwath, et al.
Veröffentlicht: (2026)

A Case Report of Promising Response to Combination Therapy With an Immune Checkpoint Inhibitor (Pembrolizumab) and Multi‐Targeted Tyrosine Kinase Inhibitor (Pazopanib) in Metastatic De‐Differentiated Chondrosarcoma
von: Matthew Youssef, et al.
Veröffentlicht: (2026)

Incidence Status and Factors Associated With Tyrosine Kinase Inhibitor‐Induced Hypertension in Patients With Renal Cell Carcinoma
von: Satoru Nakanishi, et al.
Veröffentlicht: (2025)

Novel Resistance Mechanisms to Second‐Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC
von: Fengwu Lin, et al.
Veröffentlicht: (2025)

Assessment of Treatment Outcome in Chronic Myelogenous Leukemia Patients on Tyrosine Kinase Inhibitors: Insight From a Resource Limited Setting
von: Wude Yewondwosen Awlachew, et al.
Veröffentlicht: (2025)

An Inflammatory Myofibroblastic Tumor With a Novel ALKV1180L Mutation Leading to Acquired Resistance to Tyrosine Kinase Inhibitors
von: Brittney Sharpe, et al.
Veröffentlicht: (2024)

Clinical Features and T‐Cell Repertoire of Chronic Myeloid Leukemia Patients Who Attempt Discontinuation of Tyrosine Kinase Inhibitors: The ISAC ‐ TFR Study
von: Hiroshi Ureshino, et al.
Veröffentlicht: (2025)

Budesonide, Added to PTCy‐Based Regimen, for Prevention of Acute GI GVHD After Allogeneic Stem Cell Transplantation
von: Piyanuch Kongtim, et al.
Veröffentlicht: (2025)

Quality of Life and Adherence to Tyrosine Kinase Inhibitors Among Pediatric, Adolescent, and Young Adult Chronic Myeloid Leukemia Patients: A Systematic Review
von: Rachel S. Werk, et al.
Veröffentlicht: (2025)

Durable Response to Pazopanib (Tyrosine Kinase Inhibitor) in a Patient With EWSR1::CREM Gene Fusion Positive Intra‐Abdominal Unclassified Epithelioid Sarcoma
von: Saba Shafi, et al.
Veröffentlicht: (2025)

Bruton's Tyrosine Kinase: Pathophysiological Roles and Inhibitor‐Based Therapeutic Advances
von: Simhadri Goud Gundrathi, et al.
Veröffentlicht: (2026)

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Zanubrutinib in Immune Thrombocytopenia
von: Qiu‐Sha Huang, et al.
Veröffentlicht: (2025)

Evaluation of Second‐Line Treatment for Castration‐Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors
von: Kazuro Kikkawa, et al.
Veröffentlicht: (2024)

Multi‐Targeted Kinase Inhibitor Therapy in Pediatric Bone and Soft Tissue Sarcoma Patients—A Single Centre Experience
von: Anna Mohás, et al.
Veröffentlicht: (2025)

Adverse Health Events in Chronic Myeloid Leukaemia Patients Treated With Tyrosine Kinase Inhibitors 2009–2019: A Real‐World Study From the UK 's Haematological Malignancy Research Network
von: Eleanor Kane, et al.
Veröffentlicht: (2026)

Cardiovascular Challenges in Chronic Lymphocytic Leukemia ( CLL ) Patients Undergoing Bruton Tyrosine Kinase ( BTK ) Inhibitor Therapy
von: Stefano Oliva, et al.
Veröffentlicht: (2025)

Synthesis of a Potent Bruton's Tyrosine Kinase Inhibitor Labelled With Carbon‐14 and Deuterium
von: Bachir Latli, et al.
Veröffentlicht: (2025)

Prevalence of Fms‐Like Tyrosine Kinase 3 (FLT3) Mutations in Patients With Acute Myeloid Leukaemia: A Systematic Literature Review and Meta‐Analysis
von: Juliana F. M. Lewis, et al.
Veröffentlicht: (2025)

Real‐World Outcomes of Brigatinib Compared to Alectinib as a Second‐Line Therapy After Crizotinib in Advanced Anaplastic Lymphoma Kinase Positive Non‐Small Cell Lung Cancer Patients
von: Min Jee Kim, et al.
Veröffentlicht: (2025)

Severe Precapillary Pulmonary Hypertension and Right Ventricular Failure After Hematopoietic Stem Cell Transplantation: Successful Outcomes With Aggressive Upfront Triple Therapy
von: Stine Andersen, et al.
Veröffentlicht: (2025)

The Multi‐Kinase Inhibitor GZD824 (Olverembatinib) Shows Pre‐Clinical Efficacy in Endometrial Cancer
von: Dongli Liu, et al.
Veröffentlicht: (2024)

PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma
von: Noriko Fukuhara, et al.
Veröffentlicht: (2025)

Adoptive cellular therapy after hematopoietic stem cell transplantation
von: Pongthep Vittayawacharin, et al.
Veröffentlicht: (2024)

Correction to “Induction of Resistance to Neurotrophic Tropomyosin‐Receptor Kinase Inhibitors by HMGCS2 via a Mevalonate Pathway”
Veröffentlicht: (2024)

Venetoclax combined with cladribine, idarubicin, cytarabine ( CLIA ‐ VEN ) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia
von: Benjamin J. Lee, et al.
Veröffentlicht: (2025)

Upfront immunotherapy for synchronous high‐grade glioma and B‐lymphoma in a pediatric patient with CMMRD syndrome
von: Thérèse De Vanssay, et al.
Veröffentlicht: (2024)

Treatment Effectiveness of Venetoclax‐Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real‐World Study
von: Nilanjan Ghosh, et al.
Veröffentlicht: (2024)

Efficacy and Safety of CART Cell Therapy in Aggressive B‐Cell Lymphomas Involving the Gastrointestinal Tract
von: Lixia Ma, et al.
Veröffentlicht: (2025)

Marginal Zone B‐Cell Lymphoma With Marked Plasmacytic Differentiation and Increased Large Cells in a Teenage Male With Serine/Threonine Kinase‐4 Deficiency
von: Buket Kara, et al.
Veröffentlicht: (2025)

Case of Refractory Classic Hodgkin Lymphoma With a Germline Pathogenic Monoallelic Variant in the TNFRSF13B Gene
von: Mónica Camacho‐Arias, et al.
Veröffentlicht: (2024)

Comment on: “Challenging the Odds: Long‐Term Survival in Pediatric Diffuse Midline Glioma With H3 K27M and BRAF V600 Co‐Mutations Treated With Upfront Radiotherapy and Targeted Therapy”
von: Natália Dassi, et al.
Veröffentlicht: (2026)

A Novel Dual Bruton's Tyrosine Kinase/Janus Kinase 3 Inhibitor Wj1113 and its Therapeutic Effects on Rheumatoid Arthritis
von: Chunyu Zhang, et al.
Veröffentlicht: (2025)

Pericarditis and Cardiac Tamponade in Patients Treated with First and Second Generation Bruton Tyrosine Kinase Inhibitors: An Underappreciated Risk
von: Thomas Erblich, et al.
Veröffentlicht: (2024)

Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators
von: Tara Graff, et al.
Veröffentlicht: (2025)

Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting
von: Jacopo Nanni, et al.
Veröffentlicht: (2025)

Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies
von: Oleg Demin, et al.
Veröffentlicht: (2025)

NOTCH1 Mutation Is Associated With Response to Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: A Retrospective Study
von: Clémence Haméon, et al.
Veröffentlicht: (2025)